Cargando…
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
Coronavirus disease 2019 (COVID-19) is characterized by distinct patterns of disease progression that suggest diverse host immune responses. We performed an integrated immune analysis on a cohort of 50 COVID-19 patients with various disease severity. A distinct phenotype was observed in severe and c...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for the Advancement of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402632/ https://www.ncbi.nlm.nih.gov/pubmed/32661059 http://dx.doi.org/10.1126/science.abc6027 |
_version_ | 1783566793419259904 |
---|---|
author | Hadjadj, Jérôme Yatim, Nader Barnabei, Laura Corneau, Aurélien Boussier, Jeremy Smith, Nikaïa Péré, Hélène Charbit, Bruno Bondet, Vincent Chenevier-Gobeaux, Camille Breillat, Paul Carlier, Nicolas Gauzit, Rémy Morbieu, Caroline Pène, Frédéric Marin, Nathalie Roche, Nicolas Szwebel, Tali-Anne Merkling, Sarah H. Treluyer, Jean-Marc Veyer, David Mouthon, Luc Blanc, Catherine Tharaux, Pierre-Louis Rozenberg, Flore Fischer, Alain Duffy, Darragh Rieux-Laucat, Frédéric Kernéis, Solen Terrier, Benjamin |
author_facet | Hadjadj, Jérôme Yatim, Nader Barnabei, Laura Corneau, Aurélien Boussier, Jeremy Smith, Nikaïa Péré, Hélène Charbit, Bruno Bondet, Vincent Chenevier-Gobeaux, Camille Breillat, Paul Carlier, Nicolas Gauzit, Rémy Morbieu, Caroline Pène, Frédéric Marin, Nathalie Roche, Nicolas Szwebel, Tali-Anne Merkling, Sarah H. Treluyer, Jean-Marc Veyer, David Mouthon, Luc Blanc, Catherine Tharaux, Pierre-Louis Rozenberg, Flore Fischer, Alain Duffy, Darragh Rieux-Laucat, Frédéric Kernéis, Solen Terrier, Benjamin |
author_sort | Hadjadj, Jérôme |
collection | PubMed |
description | Coronavirus disease 2019 (COVID-19) is characterized by distinct patterns of disease progression that suggest diverse host immune responses. We performed an integrated immune analysis on a cohort of 50 COVID-19 patients with various disease severity. A distinct phenotype was observed in severe and critical patients, consisting of a highly impaired interferon (IFN) type I response (characterized by no IFN-β and low IFN-α production and activity), which was associated with a persistent blood viral load and an exacerbated inflammatory response. Inflammation was partially driven by the transcriptional factor nuclear factor–κB and characterized by increased tumor necrosis factor–α and interleukin-6 production and signaling. These data suggest that type I IFN deficiency in the blood could be a hallmark of severe COVID-19 and provide a rationale for combined therapeutic approaches. |
format | Online Article Text |
id | pubmed-7402632 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | American Association for the Advancement of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-74026322020-08-19 Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients Hadjadj, Jérôme Yatim, Nader Barnabei, Laura Corneau, Aurélien Boussier, Jeremy Smith, Nikaïa Péré, Hélène Charbit, Bruno Bondet, Vincent Chenevier-Gobeaux, Camille Breillat, Paul Carlier, Nicolas Gauzit, Rémy Morbieu, Caroline Pène, Frédéric Marin, Nathalie Roche, Nicolas Szwebel, Tali-Anne Merkling, Sarah H. Treluyer, Jean-Marc Veyer, David Mouthon, Luc Blanc, Catherine Tharaux, Pierre-Louis Rozenberg, Flore Fischer, Alain Duffy, Darragh Rieux-Laucat, Frédéric Kernéis, Solen Terrier, Benjamin Science Reports Coronavirus disease 2019 (COVID-19) is characterized by distinct patterns of disease progression that suggest diverse host immune responses. We performed an integrated immune analysis on a cohort of 50 COVID-19 patients with various disease severity. A distinct phenotype was observed in severe and critical patients, consisting of a highly impaired interferon (IFN) type I response (characterized by no IFN-β and low IFN-α production and activity), which was associated with a persistent blood viral load and an exacerbated inflammatory response. Inflammation was partially driven by the transcriptional factor nuclear factor–κB and characterized by increased tumor necrosis factor–α and interleukin-6 production and signaling. These data suggest that type I IFN deficiency in the blood could be a hallmark of severe COVID-19 and provide a rationale for combined therapeutic approaches. American Association for the Advancement of Science 2020-08-07 2020-07-13 /pmc/articles/PMC7402632/ /pubmed/32661059 http://dx.doi.org/10.1126/science.abc6027 Text en Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works https://creativecommons.org/licenses/by/4.0/ https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution license (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Reports Hadjadj, Jérôme Yatim, Nader Barnabei, Laura Corneau, Aurélien Boussier, Jeremy Smith, Nikaïa Péré, Hélène Charbit, Bruno Bondet, Vincent Chenevier-Gobeaux, Camille Breillat, Paul Carlier, Nicolas Gauzit, Rémy Morbieu, Caroline Pène, Frédéric Marin, Nathalie Roche, Nicolas Szwebel, Tali-Anne Merkling, Sarah H. Treluyer, Jean-Marc Veyer, David Mouthon, Luc Blanc, Catherine Tharaux, Pierre-Louis Rozenberg, Flore Fischer, Alain Duffy, Darragh Rieux-Laucat, Frédéric Kernéis, Solen Terrier, Benjamin Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients |
title | Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients |
title_full | Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients |
title_fullStr | Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients |
title_full_unstemmed | Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients |
title_short | Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients |
title_sort | impaired type i interferon activity and inflammatory responses in severe covid-19 patients |
topic | Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402632/ https://www.ncbi.nlm.nih.gov/pubmed/32661059 http://dx.doi.org/10.1126/science.abc6027 |
work_keys_str_mv | AT hadjadjjerome impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients AT yatimnader impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients AT barnabeilaura impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients AT corneauaurelien impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients AT boussierjeremy impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients AT smithnikaia impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients AT perehelene impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients AT charbitbruno impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients AT bondetvincent impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients AT cheneviergobeauxcamille impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients AT breillatpaul impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients AT carliernicolas impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients AT gauzitremy impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients AT morbieucaroline impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients AT penefrederic impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients AT marinnathalie impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients AT rochenicolas impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients AT szwebeltalianne impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients AT merklingsarahh impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients AT treluyerjeanmarc impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients AT veyerdavid impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients AT mouthonluc impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients AT blanccatherine impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients AT tharauxpierrelouis impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients AT rozenbergflore impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients AT fischeralain impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients AT duffydarragh impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients AT rieuxlaucatfrederic impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients AT kerneissolen impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients AT terrierbenjamin impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients |